Oliver Sartor, MD

Articles

Dr. Sartor on Conclusions and Future of Sipuleucel-T in Prostate Cancer

August 28th 2017

Oliver Sartor, MD, medical oncologist at Tulane University School of Medicine, discusses conclusions drawn from an analysis of African-American patients receiving sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer and the potential for combinations with this agent.

Dr. Sartor on the Science of Sipuleucel-T for Prostate Cancer

August 18th 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the science behind the results of a study investigating sipuleucel-T (Provenge) for patients with castration-resistant prostate cancer (CRPC).

Dr. Sartor on the Next Steps with Sipuleucel-T for Prostate Cancer

August 10th 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the next steps with sipuleucel-T (Provenge) for patients with prostate cancer.

Dr. Sartor on Remaining Questions With Sipuleucel-T in mCRPC

July 21st 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the remaining questions with sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer.

Dr. Sartor on the Implications of the Analysis of Sipuleucel-T in Prostate Cancer

June 27th 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the implications of the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

Dr. Sartor on Sipuleucel-T in mCRPC

May 24th 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

Dr. Sartor on Mechanism of Action and Safety of Radium-223 in mCRPC

June 21st 2016

Oliver Sartor, MD, medical director of Tulane Cancer Center, discusses the mechanism of action of radium-223 dichloride (Xofigo) as well as its safety profile for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Sartor on Significance of Radium-223 for Community Oncologists

September 16th 2015

Oliver Sartor, MD, medical oncologist, Tulane University School of Medicine, discusses key points for community oncologists regarding radium-223 for the treatment of prostate cancer.

Dr. Sartor on Sequencing Therapies in Prostate Cancer

April 24th 2015

Oliver Sartor, MD, medical oncologist, Tulane University School of Medicine, discusses sequencing therapies and potential targets in prostate cancer.

Dr. Sartor on Distinguishing Between Symptomatic and Asymptomatic Patients

April 16th 2014

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the distinction between symptomatic and asymptomatic patients with bone metastases from prostate cancer.

Dr. Sartor on Distinguishing Between Symptomatic and Asymptomatic Patients

April 16th 2014

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the distinction between symptomatic and asymptomatic patients with bone metastases from prostate cancer.

Dr. Sartor on Provenge in Combination with Radium-223

April 1st 2014

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses a trial that would study Provenge (sipuleucel-T) in combination with radium-223 as a potential treatment option for patients with prostate cancer.

Dr. Sartor Discusses PSA Testing for Prostate Cancer

March 17th 2014

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the controversies surrounding PSA screening for prostate cancer.

Dr. Sartor on Progress for the Treatment of Prostate Cancer

September 3rd 2013

A. Oliver Sartor, MD, Director of the Tulane Cancer Center, discusses the recent progress for the treatment of prostate cancer.

Dr. Sartor on the Mechanism of Action of Radium-223

July 12th 2013

A. Oliver Sartor, MD, Director of the Tulane Cancer Center, describes the mechanism of action of radium-223 for bone metastases from prostate cancer.

Dr. Oliver Sartor Discusses PSA Screening

May 22nd 2012

Dr. Oliver Sartor, from Tulane Cancer Center, Discusses Prostate-Specific Antigen (PSA) Screening

Dr. Sartor on Combining Radium-223 and Provenge

April 25th 2012

Dr. Oliver Sartor, from Tulane Cancer Center, Discusses a New Trial Combining Radium-223 and Provenge

Dr. Sartor on Radium-223 in Early Prostate Cancer

April 4th 2012

Dr. Oliver Sartor, from Tulane Cancer Center, Discusses Radium-223 in Early Prostate Cancer

Dr. Sartor on Patients in the ALSYMPCA Radium-223 Trial

December 20th 2011

Dr. Oliver Sartor, from Tulane Cancer Center, Describes Patients in the ALSYMPCA Radium-223 Trial

Dr. Sartor Discusses Prostate Cancer Drug Combinations

November 29th 2011

Dr. Oliver Sartor from Tulane Cancer Center Discusses Prostate Cancer Drug Combinations